| scholarly article | Q13442814 |
| review article | Q7318358 |
| P2093 | author name string | Elinore F McCance-Katz | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | HIV | Q15787 |
| hepatitis C | Q154869 | ||
| anti-retroviral agent | Q50430310 | ||
| patient | Q181600 | ||
| opioid | Q427523 | ||
| Hepatitis C virus | Q708693 | ||
| P304 | page(s) | S89-95 | |
| P577 | publication date | 2005-07-01 | |
| P1433 | published in | Clinical Infectious Diseases | Q5133764 |
| P1476 | title | Treatment of opioid dependence and coinfection with HIV and hepatitis C virus in opioid-dependent patients: the importance of drug interactions between opioids and antiretroviral agents | |
| P478 | volume | 41 Suppl 1 |
| Q36063045 | Antiretroviral HIV treatment and care for injecting drug users: an evidence-based overview |
| Q37305173 | Are opioid dependence and methadone maintenance treatment (MMT) documented in the medical record? A patient safety issue |
| Q36263653 | Association between hepatitis C virus and opioid use while in buprenorphine treatment: preliminary findings |
| Q38562886 | Considerations on the role of buprenorphine in recovery from heroin addiction from a UK perspective |
| Q37142229 | Critical issues in the treatment of hepatitis C virus infection in methadone maintenance patients |
| Q35220086 | Design and synthesis of a bivalent ligand to explore the putative heterodimerization of the mu opioid receptor and the chemokine receptor CCR5. |
| Q42076090 | Determination and Validation of a Solid-phase Extraction Gas Chromatography-mass Spectrometry for the Quantification of Methadone and Its Principal Metabolite in Human Plasma |
| Q33640426 | Drug interactions between antiretroviral medications and medications used in the treatment of drug addiction: research needs |
| Q37000733 | Drug interactions in the management of HIV infection: an update |
| Q35906594 | Drug interactions of clinical importance among the opioids, methadone and buprenorphine, and other frequently prescribed medications: a review |
| Q37383949 | Efavirenz: a decade of clinical experience in the treatment of HIV. |
| Q24649164 | Effect of rifampin and nelfinavir on the metabolism of methadone and buprenorphine in primary cultures of human hepatocytes |
| Q57709954 | HCV/HIV coinfection among people who inject drugs and enter opioid substitution treatment in Greece: prevalence and correlates |
| Q35009465 | HIV-1 neuropathogenesis: glial mechanisms revealed through substance abuse |
| Q36069676 | HIV-gp120 and physical dependence to buprenorphine |
| Q35389163 | Hepatitis infection in the treatment of opioid dependence and abuse. |
| Q35738878 | Interaction between buprenorphine and atazanavir or atazanavir/ritonavir. |
| Q44924769 | Interactions between buprenorphine and antiretrovirals. I. The nonnucleoside reverse-transcriptase inhibitors efavirenz and delavirdine |
| Q44924772 | Interactions between buprenorphine and antiretrovirals. II. The protease inhibitors nelfinavir, lopinavir/ritonavir, and ritonavir |
| Q37045335 | Interactions between buprenorphine and antiretrovirals: nucleos(t)ide reverse transcriptase inhibitors (NRTI) didanosine, lamivudine, and tenofovir. |
| Q37045349 | Lack of clinically significant drug interactions between nevirapine and buprenorphine |
| Q36641870 | Mechanism of ritonavir changes in methadone pharmacokinetics and pharmacodynamics: II. Ritonavir effects on CYP3A and P-glycoprotein activities |
| Q37125615 | Medical consequences of drug abuse and co-occurring infections: research at the National Institute on Drug Abuse |
| Q64267726 | Medications for Treatment of Opioid Use Disorder among Persons Living with HIV |
| Q36637864 | Methadone metabolism and clearance are induced by nelfinavir despite inhibition of cytochrome P4503A (CYP3A) activity |
| Q34604652 | Methadone pharmacokinetics are independent of cytochrome P4503A (CYP3A) activity and gastrointestinal drug transport: insights from methadone interactions with ritonavir/indinavir |
| Q39020153 | Patterns of drug use and HIV infection among adults in a nationally representative sample |
| Q37419542 | Pharmacogenomics of CYP3A: considerations for HIV treatment |
| Q45330127 | Pharmacokinetic Considerations for Combining Antiretroviral Therapy, Direct-Acting Antiviral Agents for Hepatitis C Virus, and Addiction Treatment Medications |
| Q36543096 | Pharmacokinetic interactions between HIV antiretroviral therapy and drugs used to treat opioid dependence |
| Q35738885 | Rifampin, but not rifabutin, may produce opiate withdrawal in buprenorphine-maintained patients |
| Q35024508 | The impact of integrated HIV care on patient health outcomes. |
| Q35061983 | Therapeutic drug monitoring of protease inhibitors and efavirenz in HIV-infected individuals with active substance-related disorders. |
| Q27489073 | Underlying Pathophysiology of HCV Infection in HIV-Positive Drug Users |
| Q48296522 | Usefulness of methadone plasma concentration measurement in patients receiving nevirapine or efavirenz |
Search more.